Better representation holds the key to breaking bias around women’s health
This World Health Day (April 7th), I took a moment to celebrate the scientists and researchers battling under-representation to improve health outcomes for women. In doing so, I was thinking about the millions of women around the world who, on this day, continued to experience pain that is both ignored and under-researched.


Women’s representation matters everywhere, but it is particularly vital in scientific research, where it can lead to more accurate results that produce better health outcomes. In addressing conditions that disproportionately affect women, technological innovation is helping to fill important gaps in our understanding.
However, truly representative science and health-care product development can only be achieved with more women being studied, on the proverbial examination table; more women asking scientific questions and running tests, at the lab table; and more women making decisions about where to invest, at the boardroom table.
The gender pain gap
Women’s health issues are often different from men's. Aside from the obvious things related to intimate wellness, pregnancy, menstruation and menopause, women are in pain more often and more acutely than men. Gastrointestinal conditions such as Irritable Bowel Syndrome disproportionately impact women, owing to anatomical and hormonal differences. Migraines are nearly three times as common in women. They can be triggered or exacerbated by factors including menstruation, pregnancy, menopause and oral contraceptives.
In the UK, we found that more than one in two women feel their pain has been dismissed because of their gender. The issue is particularly acute among young women (aged 18-24), 81% of whom feel their pain has not been taken seriously by a health-care professional. There are many reasons for this, and under-representation in the research and development (R&D) process for women’s health solutions is undoubtedly one of them.
For years, the ‘scientific norm’ was the white male body. It was widely believed that findings for men would apply to everyone. However, we now know, for example, that hormones related to women’s monthly cycles might impact clinical results. Despite this, as recently as 2022, the UK government’s Women’s Health Strategy found a ‘male as default’ approach in research and clinical trials.
It is, therefore, clear why the scientific establishment knows less about pain that is predominantly experienced by women, or how conditions affect men and women differently.
The result? Conditions go undiagnosed, women suffer in silence and—in some cases—experience poor mental health from the anxiety or stigma symptoms can cause. Even when sufferers do seek help, their symptoms may be dismissed or their conditions normalised, so correct diagnoses and treatment can take years.
The impact of all this is not just personal. With only one-fifth of women at work feeling that they can discuss their pain with a manager or Human Resources, careers and the wider economy suffer too. The NHS estimates that absenteeism due to female-specific pain costs the economy £11bn per year. This is more than a health problem—it’s a societal and economic one.
A gap also exists at the clinical trial and product-testing stage, which has real-world consequences for women’s health. One 2022 Harvard Medical School study found that women only accounted for about 40% of participants in clinical trials for three diseases that affect women more than men.
Innovation as part of the solution
There is a long way to go, but important steps are being taken and focused innovation is already delivering better solutions for women.
With the wider health-tech trend of women being better able to track their own health through monitoring apps, wearable devices and digital-health platforms, technology is broadening women’s access to health care.
For the innovators developing solutions, from AI-powered ultrasounds to future-ready diagnostic tools and gut-informed nutrition, better understanding of women’s conditions is slowly but surely driving product innovation to help improve the quality of health care.
This work is also improving the quality of self-care, empowering women to take a more holistic view of their health. It goes beyond better products being accessible over the counter. With more innovative services available from health-care providers in the community, including pharmacies, women—along with their families and communities—can play a bigger role in preventing ill health and fostering wellness.
As society pivots toward a more prevention-based approach to women’s health, the pressure on formal health care will decrease, which, in turn, has benefits for the economy, the environment, and beyond.
But to speed up the introduction of health-care products that will bring societal benefits, we need more women in the early stages of the innovation process. This means more women working in R&D, and more in STEM, where globally, women make up just 28% of the workforce. Research published last month by the Department for Education found that the gap between boys and girls in maths and science subjects in Year 5 and Year 9 in England is ‘significantly larger’ than it was five years ago. This suggests that the outlook for near-term improvement is not promising.
Overcoming the barriers
Systemic barriers that hinder the access of women and girls to scientific careers mean this shift may not be easy to achieve. I had a very early role model in science—my mom, who studied at nursing school while raising my sisters and me, but not everyone has a straightforward academic and career journey.
More women as leaders in scientific fields will mean more perspectives, experiences and creativity—which, in turn, will lead to better science and better solutions. That is a win-win for everyone, driving better business, as well as better health outcomes.
Dr Angela Naef, chief R&D officer at Reckitt

Angela Naef joined Reckitt as chief R&D officer in September 2020, where she is responsible for elevating Reckitt’s science capability and platforms as well as for driving external partnerships.
Dr Naef brings to Reckitt over 23 years of diverse senior leadership experience in product- and business-development roles. Most recently, she spent ten years at DuPont, in various technical and commercial leadership roles, where she led the Nutrition & Biosciences Global Technology and Innovation organisation. Dr Naef has a strong track record of accelerating innovation in the areas of food and nutrition sciences, materials, health and clinical sciences, regulatory and biotechnology. She is a passionate advocate for diversity and inclusion and actively works on STEM education to inspire the next generation of new scientists, engineers and experts.